Sulfonylureas and risk of falls and fractures: a systematic review
- PMID: 23609875
- DOI: 10.1007/s40266-013-0081-0
Sulfonylureas and risk of falls and fractures: a systematic review
Abstract
Background: Sulfonylureas have been linked to increased risk of hypoglycemia. Hypoglycemia may lead to falls, and falls may lead to fracture. However, studies quantifying the association between sulfonylureas and fractures are sparse and yield inconsistent results.
Objective: The purpose of this article was to review the literature regarding sulfonylurea use and falls or fall-related fractures among older adults with type 2 diabetes mellitus and to delineate areas for future research.
Data sources: We searched MEDLINE (1966-March 2012) and CINAHL (1937-March 2012) for studies of patients with type 2 diabetes mellitus living in the community or nursing homes.
Study selection: The search algorithms combined three domains: (1) diabetic patients, (2) sulfonylurea medications, and (3) fractures or falls. We included only publications in English that pertained to human subjects. We found 9 randomized trials and 12 non-experimental studies that met the inclusion criteria.
Study appraisal and synthesis methods: The guidelines provided by the Cochrane handbook or Agency for Healthcare Research and Quality (AHRQ) Methods Guide are too general to distinguish the quality of included non-experimental studies, so we developed several specific domains based on those general guidelines. These domains included study design, study population, follow-up time, comparison group, exposure definition, outcome definition, induction period, confounding adjustment, and attrition or missing data. The data were not amenable to a meta-analysis.
Results: No clinical trials included fracture as a primary endpoint. Most clinical trials excluded older adults. Most studies were not designed to evaluate the risk of sulfonylureas on fractures or falls. Studies did not show an increased risk of falls/fractures with sulfonylurea.
Limitations: The data available from existing studies suffer from methodological limitations including insufficient events, lack of primary endpoints, exclusion of older adults, and lack of clarity or inappropriate comparison groups.
Conclusion: Future studies are needed to appropriately estimate the effect of sulfonylureas on falls or fall-related fractures in older adults who are at increased risk for hypoglycemia, the hypothesized mechanism for fractures related to sulfonylurea therapy.
Similar articles
-
Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus.Diabetes Res Clin Pract. 2015 Aug;109(2):411-9. doi: 10.1016/j.diabres.2015.05.009. Epub 2015 May 12. Diabetes Res Clin Pract. 2015. PMID: 26008723
-
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.Ann Intern Med. 2015 Nov 3;163(9):663-72. doi: 10.7326/M15-0308. Epub 2015 Oct 13. Ann Intern Med. 2015. PMID: 26457538
-
Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.Clin Invest Med. 2016 Apr 2;39(2):E48-62. doi: 10.25011/cim.v39i2.26481. Clin Invest Med. 2016. PMID: 27040861 Review.
-
Effectiveness and safety of vitamin D in relation to bone health.Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088161 Free PMC article. Review.
-
Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.Curr Med Res Opin. 2014 May;30(5):785-9. doi: 10.1185/03007995.2013.875464. Epub 2014 Jan 17. Curr Med Res Opin. 2014. PMID: 24328429
Cited by
-
Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures.Medicina (Kaunas). 2024 Feb 26;60(3):393. doi: 10.3390/medicina60030393. Medicina (Kaunas). 2024. PMID: 38541119 Free PMC article. Review.
-
Treatment of Diabetes and Osteoporosis-A Reciprocal Risk?Biomedicines. 2022 Sep 5;10(9):2191. doi: 10.3390/biomedicines10092191. Biomedicines. 2022. PMID: 36140292 Free PMC article. Review.
-
Diabetes and Bone Involvement in Primary Hyperparathyroidism: Literature Review and Our Personal Experience.Front Endocrinol (Lausanne). 2021 Apr 19;12:665984. doi: 10.3389/fendo.2021.665984. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33953702 Free PMC article. Review.
-
The Interplay Between Bone and Glucose Metabolism.Front Endocrinol (Lausanne). 2020 Mar 24;11:122. doi: 10.3389/fendo.2020.00122. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32265831 Free PMC article. Review.
-
A Recent Achievement In the Discovery and Development of Novel Targets for the Treatment of Type-2 Diabetes Mellitus.J Exp Pharmacol. 2020 Jan 10;12:1-15. doi: 10.2147/JEP.S226113. eCollection 2020. J Exp Pharmacol. 2020. PMID: 32021494 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
